Please provide your email address to receive an email when new articles are posted on . A secondary analysis of the phase 2 PACIFIC-STROKE trial showed that asundexian is effective for the secondary ...
October 5, 2011 (Bethesda, Maryland) - The aspirin-clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis) arm of a randomized secondary-prevention trial of patients with subcortical stroke has been ...
The goal of SPS3 was to learn if combination antiplatelet therapy (aspirin and clopidogrel) is more effective than aspirin alone for the prevention of recurrent stroke and cognitive decline, and if ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results